



alzchem  
group

AGILE SCIENCE PURE RESULTS

alzchem  
group



Q1

2024

**ANDREAS NIEDERMAIER, CEO**  
**DR. GEORG WEICHSELBAUMER, CSO**  
**ANDREAS LÖSLER, CFO**

April 30, 2024

## DISCLAIMER

### CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, Alzchem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA – ANALYST PRESENTATION Q1 2024

- I. **Executive Summary**
- II. Business and financial details
- III. Back-Up

# HIGHLIGHTS

Business development continues at a high level



Group sales stable at previous year's level

EBITDA increased materially by 32% to 24.9 m€



Segment Specialty Chemicals highly contributes to the groups' earnings growth



34.4 m€ investment subsidy by EU-Commission as part of ASAP program



Free Cashflow strongly positive and significantly higher compared to prior year





Outlook 2024 confirmed: further growth in sales, EBITDA and EBITDA-margin expected



Considerable positive performance of the share price

# "VERBUND" SYSTEM – FULLY INTEGRATED BUSINESS MODEL

Fine Chemicals and Pharma




**Bioselect®**

Highly purified form of guanidine salts



**DYHARD®**

Hardeners and accelerators in powder, paste and liquid form



**DCD FOR METFORMIN**

Versatile intermediate in various markets including the pharmaceutical industry



**GUANIDINE-SALTS**

Fuel for airbags, key production of the intermediate product



**NITRO-GUANIDINE**

Intermediates for explosives and agrochemical products



**MELFLOCK® ALZOFIX®**

Applications in waste water treatment, paper, textile and leather industry



**THIOUREA**

Various applications incl. flotation agent and pharmaceutical raw material



# INVESTMENT GRANT BY EU COMMISSION

As a part of ASAP ("Act in Support of Ammunition Production")



## Alzchem Group AG awarded EUR 34.4 million investment grant by EU Commission

- Part of ASAP funding instrument
- Funding for the project has been provisionally approved by the EU Commission based on a Europe-wide selection process
- Funds to be used over two and a half year investment period
- **Capex Volume** : ~ 75 million euros
- Increase production capacity of nitroguanidine
- Modernize and expand facilities for production of guanidine nitrate - Guanidine nitrate is a precursor of nitroguanidine
- Final allocation and funding agreement is expected to take place in Q2 2024

AGENDA – ANALYST PRESENTATION Q1 2024

- I. Executive Summary
- II. Business and financial details**
- III. Back-Up





NITRALZ®

Perlka®  
CALCIUM CYANAMIDE

CaD

## **BASICS & INTERMEDIATES**


The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.

# BASICS & INTERMEDIATES SEGMENT (in M€)


Challenging market environment




## SALES




## EBITDA



## SALES



## EBITDA



## SALES ANALYSIS

	DELTA Q1
Volume	- 6.6%
Price	- 7.1%
Currency	- 0.3%

## COMMENTS

- The decline in sales (-14,0%) is proportionally caused by price escalation clauses and reduced quantities in some areas
- Metallurgy volumes affected by the tense economic situation of the European steel industry
- Building Block Dicyandiamide and Perlka® developed positively compared to prior year
- EBITDA decrease (-35,2%) mainly due to reduced volumes in NITRALZ® business resulting from strong market pressure. Products face intense competition of Asian companies with different pricing structure



**CREAMINO** Dormex® Bioselect® **DYHARD®**  **Creapure®**

## **SPECIALTY CHEMICALS**


The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.

# SPECIALTY CHEMICALS SEGMENT (in M€)


Specialty Chemicals drives growth and profitability course of Alzchem




## SALES




## SALES



## EBITDA



## EBITDA



## SALES ANALYSIS

	DELTA Q1
Volume	+7.3%
Price	+ 1.5%
Currency	- 0.4%

## COMMENTS

- Specialty Chemicals sector again on proven growth path with strong increase in sales (9%) and EBITDA (+42%)
- Further volume growth in Human and Animal Nutrition as well as in Defense sector
- Bioselect® and DYHARD® can reverse negative sales trend of prior year and are back on growth path
- Custom Manufacturing is highly affected by the economic downturn in the chemical industry and high stockpile – concentration on highly specialized products as a chance
- Planned capacity expansion with 35 m€ support of the European Union (ASAP-Program) for production of guanidine salts in Germany
- Further gradual increase of creatine capacities started



## **OTHER & HOLDING**


The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.

# OTHER & HOLDING SEGMENT (in M€)

Segment in line with Outlook




## SALES




## SALES



## EBITDA



## EBITDA



## COMMENTS

- 2024 sales are ~ 7 % above previous year's level based on pass-through of cost increases in pricing
- EBITDA at the expected level with no special impacts

# FINANCIAL OVERVIEW

Sustained growth in profitability



## Alzchem Group

	Q1 2023	Q1 2024	yoy %
SALES (in M€)	150,4	150,1	-0,2%
EBITDA (in M€)	18,9	24,9	+31,7%
EBITDA margin (in %)	12,6%	16,6%	+4,0 pp
Earnings per Share (in €)	0,76	1,20	+58,4%

## SALES ANALYSIS

## DELTA Q1

Volume	1.9%
Price	-1.8%
Currency	-0.3%


- Sales in Q1 2024 at previous year's level with different developments in our business segments; volume growth almost offset by price impacts
- Segment Specialty Chemicals continues the strong performance of the last financial year and recorded a further increase in sales (+8.4%) and EBITDA (+41.6%)
- Significantly positive impacts on earnings especially due last years capacity increase in Human Nutrition, high demand for Animal Nutrition and Defense
- Higher portion of Specialty Chemical sales led to an increase in EBITDA-margin from 12.6% to 16.6%
- Improvement in financial result together with the development in EBITDA led to a strong increase in net result and earnings per share

# BALANCE SHEET (in M€)


## Working capital reduction and increase in equity ratio



### ASSETS



### LIABILITIES



- Balance sheet total increased by 23.1 M€ compared to 31/12/2023 with opposing development of current and non-current assets
- Non current assets mainly impacted by reduction of deferred tax assets caused by interest-related decline in pension obligation
- Inventories significantly reduced as a result of volume and price declines
- Trade receivables follow high sales in Q1/2024; factoring still on low level;


- Further improvement in equity ratio from 38.5% (31/12/2023) to 40.0%
- Besides the good result achieved in Q1/2024 (+12.2 M€), the increase in equity was also positively influenced by development of interest for pension provision (+3.4 M€ after deduction of deferred taxes)
- Increase in interest rate for pension provision from 3.2% to 3.5% at current period led to lower pension obligation (-4.5 M€)
- Current liabilities follow higher business volume; repayment of non-current bank liabilities on schedule



# CASHFLOW (in M€)



Very stable financing situation paves the way for upcoming capex projects



- Strong increase of 23.3 M€ in operating cashflow due to positive operating result in Q1/2024 – working capital reduction has a positive effect of 14.2 M€ on operating cashflow compared to Q1/2023
- Investment activities start increasing again after a year of cautious investing behavior especially for capacity expansions, infrastructure and a new PV park in Trostberg – cashflow from investing activity in first quarter 2024 at 6.9 M€


- Free cashflow increased to 26.6 M€ due to strong operating cashflow (previous year: 5.4 M€)
- Cashflow from financing activities of 2.4 M€ contains mainly repayments of long-term loans and lease liabilities and is much lower compared to last year where refinancing and repayments of short-term loans were main influencer
- Cash and cash equivalents strongly increased by 24.1 M€ and surpluses partially were invested in interest-bearing and short-term investments

# OUTLOOK 2024 (in M€)


Outlook confirmed: Growth in sales, EBITDA and EBITDA-margin expected



## SALES



## EBITDA



## COMMENTS

- Development in Q1 2024 confirmed our outlook
- The Outlook is based on following assumptions:
  - ✓ No occurrence of a global recession
  - ✓ Price development of costs for raw materials, logistics and electricity stable at the level of the last quarter of 2023
  - ✓ Existing product registrations remain in place, new registrations applied for will be granted
  - ✓ Availability of raw materials and logistics
  - ✓ Ukraine war does not deliver further interruptions
- Products in Specialty chemicals continue to be the growth driver of Alzchem in sales and EBITDA
  - ✓ Creapure®, Creamino® and Nitroguanidin will support growth in volume, sales and EBITDA
- Sales in the Basics & Intermediates segment decline slightly, mainly due to price escalation clauses
- Sales shift into Specialty Chemicals will also contribute to an increase in overall group EBITDA-margin – up to 15,8%

# FINANCIAL CALENDAR

## Upcoming dates\*



APR 30	2024	Berenberg Fireside Chat
APR 30	2024	Kepler Cheuvreux Investor Group Call
MAY 7	2024	Annual General Meeting
MAY 13-15	2024	Frühjahrskonferenz
JUN 6-7	2024	Warburg Highlights Konferenz
AUG 1	2024	Quarterly Statement 2 <sup>nd</sup> Quarter 2024
SEP 23	2024	Baader Investment Conference
SEP 25	2024	Berenberg and Goldman Sachs German Corporate Conference
NOV 7	2024	Quarterly Statement 3 <sup>th</sup> Quarter 2024
NOV 13	2024	Münchener Kapitalmarkt Konferenz
NOV 25-26	2024	Deutsches Eigenkapitalforum

\*subject to change

# FEEDBACK

We appreciate your feedback



Were your expectations met?  
Are you missing any content?

**WE APPRECIATE YOUR FEEDBACK!**

[Link](#)

QR-Code



**AGILE SCIENCE  
PURE RESULTS**

**alzchem  
group**



Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

[ir@alzchem.com](mailto:ir@alzchem.com)

AGENDA – ANALYST PRESENTATION Q1 2024

- I. Executive Summary
- II. Business and financial details
- III. Back-Up**

# BALANCE SHEET

## Alzchem Group




ALZCHEM GROUP (IN T€)	31.12.2023	31.03.2024	Deviation	
Intangible assets	3.664	3.751	87	2,4%
Tangible assets	177.281	176.798	-483	-0,3%
Investment properties				
Right of use (assets)	4.855	4.784	-71	-1,5%
Investments accounted for using the equity method				
Financials assets	6	6		
Trade receivables				
Other receivables	1.371	1.225	-146	-10,6%
<i>there of Deferred tax assets for pensions provisions</i>				
Deferred tax assets	20.921	19.282	-1.638	-7,8%
<b>SUM NON-CURRENT ASSETS</b>	<b>208.096</b>	<b>205.846</b>	<b>-2.250</b>	<b>-1,1%</b>
Inventories	107.479	97.393	-10.086	-9,4%
Trade receivables	75.212	88.388	13.176	17,5%
Financial assets	0	0	0	-223,5%
Other receivables	19.239	18.759	-480	-2,5%
Income tax receivables	2.769	1.425	-1.343	-48,5%
Cash and cash equivalents	11.883	35.998	24.115	202,9%
Assets classified as held for sale				
Other assets				
<b>SUM CURRENT ASSETS</b>	<b>216.581</b>	<b>241.963</b>	<b>25.381</b>	<b>11,7%</b>
<b>SUM ASSETS</b>	<b>424.677</b>	<b>447.809</b>	<b>23.132</b>	<b>5,4%</b>

ALZCHEM GROUP (IN T€)	31.12.2023	31.03.2024	Deviation	
Share capital	101.763	101.763		
<b>RETAINED EARNINGS (+) / LOSS (-)</b>	<b>144.979</b>	<b>157.173</b>	<b>12.194</b>	<b>8,4%</b>
Other comprehensive income	-21.639	-18.416	3.223	-14,9%
Own shares				
<b>SHARE TO THE SHAREHOLDERS</b>	<b>161.625</b>	<b>177.041</b>	<b>15.417</b>	<b>9,5%</b>
Non-controlling interests	1.934	1.977	43	2,2%
<b>SUM EQUITY</b>	<b>163.559</b>	<b>179.019</b>	<b>15.459</b>	<b>9,5%</b>
Provisions for pensions	100.294	95.775	-4.519	-4,5%
Other provisions	19.691	20.972	1.281	6,5%
Loans	48.665	46.457	-2.208	-4,5%
Finance lease liabilities	3.377	3.250	-127	-3,8%
Trade liabilities				
Other liabilities	171		-171	-100,0%
Deferred tax liabilities	6.289	6.500	211	3,4%
<b>SUM NON-CURRENT LIABILITIES</b>	<b>178.487</b>	<b>172.954</b>	<b>-5.533</b>	<b>-3,1%</b>
Other provisions	3.537	2.997	-540	-15,3%
Loans	8.833	9.288	455	5,2%
Finance lease liabilities	1.613	1.669	57	3,5%
Finance liabilities				
Trade liabilities	31.554	41.551	9.997	31,7%
Other liabilities	28.930	29.668	738	2,6%
Income tax liabilities	8.164	10.662	2.498	30,6%
<b>SUM CURRENT LIABILITIES</b>	<b>82.631</b>	<b>95.835</b>	<b>13.205</b>	<b>16,0%</b>
<b>Sum EQUITY AND LIABILITIES</b>	<b>424.677</b>	<b>447.808</b>	<b>23.132</b>	<b>5,4%</b>

# PENSION ACCOUNTING (IFRS)

Alzchem Group (M€)



- Interest rates increased from 3.2% to 3.5% and led to a net pension decrease of 4.8 M€
- Pension trend (2.25%) and salary trend (3.00%) remain unchanged compared to December 31<sup>st</sup>, 2023
- Pension payments develop as expected with 0.6 M€ - pension obligation has a long maturity with approx. 30 years payout period



# INCOME STATEMENT

## Alzchem Group



ALZCHEM GROUP (IN T€)	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Deviation (Q1)	
Revenue	150.432	126.599	120.824	142.794	150.064				-368	0%
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	916	9.105	147	-13.972	-6.521				-7.436	-812%
Other income	5.574	1.906	3.104	3.274	3.558				-2.016	-36%
Raw materials and consumables used	-76.159	-62.374	-48.544	-38.067	-53.237				22.922	-30%
Employee benefits expense	-35.262	-36.012	-34.678	-39.684	-40.589				-5.326	15%
Other expense	-26.583	-21.352	-21.317	-29.295	-28.367				-1.783	7%
<b>EBITDA</b>	<b>18.917</b>	<b>17.872</b>	<b>19.534</b>	<b>25.049</b>	<b>24.910</b>				<b>5.992</b>	<b>32%</b>
Depreciation expense	-6.320	-6.335	-6.574	-6.670	-6.534				-215	3%
Impairment										
<b>EBIT</b>	<b>12.598</b>	<b>11.537</b>	<b>12.960</b>	<b>18.379</b>	<b>18.375</b>				<b>5.778</b>	<b>46%</b>
Investment income										
Other interest and similar income	49	106	661	-434	292				243	493%
Other interest and similar expense	-1.882	-1.661	-1.586	-2.537	-1.454				427	-23%
<b>Financial result</b>	<b>-1.832</b>	<b>-1.555</b>	<b>-925</b>	<b>-2.971</b>	<b>-1.162</b>				<b>670</b>	<b>-37%</b>
Result from associates										
<b>Result from ordinary business</b>	<b>10.765</b>	<b>9.982</b>	<b>12.035</b>	<b>15.407</b>	<b>17.213</b>				<b>6.448</b>	<b>60%</b>
Taxes on income and profit	-3.055	-2.742	-3.379	-4.222	-4.977				-1.922	63%
<i>thereof income tax</i>	-2.946	-2.716	-3.015	-6.431	-4.463				-1.516	51%
<i>thereof change from deferred taxes</i>	-109	-26	-364	2.209	-514				-405	372%
<b>Annual result</b>	<b>7.710</b>	<b>7.240</b>	<b>8.656</b>	<b>11.185</b>	<b>12.237</b>				<b>4.526</b>	<b>59%</b>
<i>thereof minority interests</i>	43	43	43	43	43					
<i>thereof shares held by shareholders</i>	7.667	7.197	8.613	11.142	12.194				4.526	59%
<b>Result per share in EUR</b>	<b>0,76 €</b>	<b>0,71 €</b>	<b>0,85 €</b>	<b>1,09 €</b>	<b>1,20 €</b>					

# INCOME STATEMENT

## Alzchem Group



### ALZCHEM GROUP (IN T€)

	Q1 2023	Q1 2024	Deviation (QoQ)	
Revenue	150.432	150.064	-368	-0,2%
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	916	-6.521	-7.436	-812,0%
Other income	5.574	3.558	-2.016	-36,2%
Raw materials and consumables used	-76.159	-53.237	22.922	-30,1%
Employee benefits expense	-35.262	-40.589	-5.326	15,1%
Other expense	-26.583	-28.367	-1.783	6,7%
<b>EBITDA</b>	<b>18.917</b>	<b>24.910</b>	<b>5.992</b>	<b>31,7%</b>
Depreciation expense	-6.320	-6.534	-215	3,4%
Impairment	0	0	0	
<b>EBIT</b>	<b>12.598</b>	<b>18.375</b>	<b>5.778</b>	<b>45,9%</b>
Investment income	0	0	0	
Other interest and similar income	49	292	243	493,0%
Other interest and similar expense	-1.882	-1.454	427	-22,7%
<b>Financial result</b>	<b>-1.832</b>	<b>-1.162</b>	<b>670</b>	<b>-36,6%</b>
Result from associates	0	0	0	
<b>Result from ordinary business</b>	<b>10.765</b>	<b>17.213</b>	<b>6.448</b>	<b>59,9%</b>
Taxes on income and profit	-3.055	-4.977	-1.922	62,9%
<i>thereof income tax</i>	-2.946	-4.463	-1.516	51,5%
<i>thereof change from deferred taxes</i>	-109	-514	-405	371,6%
<b>Annual result</b>	<b>7.710</b>	<b>12.237</b>	<b>4.526</b>	<b>58,7%</b>
<i>thereof minority interests</i>	43	43	0	0,0%
<i>thereof shares held by shareholders</i>	7.667	12.194	4.526	59,0%
<b>Result per share in EUR</b>	<b>0,76 €</b>	<b>1,20 €</b>	<b>0</b>	<b>58,4%</b>

# CASHFLOW STATEMENT

## Alzchem Group



### CASHFLOW (IN M€)

	Q1 2023	Q1 2024
<b>Consolidated earnings before taxes</b>	<b>10.765</b>	<b>17.213</b>
Depreciation on fixed and intangible assets	6.320	6.534
Decrease in pension provisions	-564	-633
Loss (+) / Profit (-) from the sale of non-current assets	-1	-2
Other non-cash income (-) and expenses (+)	1.460	3.109
Financial result	1.832	1.162
Interests & Taxes	-2.669	-953
Increase (+) / Decrease (-) Net Working Capital	-6.899	7.019
<b>Cashflow from ongoing operations (Net cash flow)</b>	<b>10.245</b>	<b>33.450</b>
Cash outflows for investments in fixed assets	-4.810	-6.896
Cash inflows from the sale of fixed assets	-28	2
Cash inflows from the disposal of investments		
<b>Cashflow from investing activity</b>	<b>-4.838</b>	<b>-6.894</b>
<b>Free cashflow</b>	<b>5.407</b>	<b>26.556</b>
Deposits (+) / Repayment (-) bank loans long-term	30.000	
Repayment of bank loans long-term	-2.514	-1.771
Deposits (+) / Repayment (-) from short-term financing lines	-33.242	
Dividend payments		
Payment of reduction in leasing liabilities	-456	-473
Payments for the acquisition of own shares (incl. transaction costs)		
Payments to non-controlling interests	-171	-171
<b>Cashflow from financing activity</b>	<b>-6.383</b>	<b>-2.415</b>
<b>Net increase / decrease in cash and cash equivalents</b>	<b>-976</b>	<b>24.141</b>

# SEGMENT OVERVIEW BY QUARTER

## Alzchem Group



### SALES


SALES	2022				2023				2024				Deviation PY (Q1)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	T€	%
Basics & Intermediates	57.441	57.927	59.557	52.614	57.337	46.038	44.271	44.538	49.299				-8.037	-14%
Specialty Chemicals	65.279	76.214	72.967	73.902	85.783	73.172	69.545	91.302	92.961				7.178	8%
Other and Holding	6.675	6.294	6.670	6.684	7.312	7.389	7.007	6.955	7.804				491	7%
<i>Group Consolidation</i>														
<b>Alzchem Group</b>	<b>129.395</b>	<b>140.435</b>	<b>139.193</b>	<b>133.200</b>	<b>150.432</b>	<b>126.599</b>	<b>120.824</b>	<b>142.794</b>	<b>150.064</b>				<b>-368</b>	<b>0%</b>

### EBITDA

EBITDA	2022				2023				2024				Deviation PY (Q1)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	T€	%
Basics & Intermediates	2.841	853	-2.621	3.910	2.780	2.410	1.065	3.275	1.802				-979	-35%
Specialty Chemicals	14.267	16.322	14.637	7.789	16.020	14.938	18.534	23.727	22.684				6.664	42%
Other and Holding	-139	830	1.038	230	475	438	721	-1.171	538				63	13%
<i>Group Consolidation</i>	103	-200	-905	2.487	-357	88	-793	-802	-113				244	68%
<b>Alzchem Group</b>	<b>17.072</b>	<b>17.805</b>	<b>12.149</b>	<b>14.416</b>	<b>18.918</b>	<b>17.874</b>	<b>19.528</b>	<b>25.029</b>	<b>24.911</b>				<b>5.993</b>	<b>32%</b>

# ALZCHEM GROUP LOCATIONS

Production sites and sales companies



Production facilities in Germany (4) and Sweden (1) and HQ in Trostberg (GER)

- SALES COMPANY
- PRODUCTION SITE

# IMPLEMENTING OPERATING TARGETS 2024

Focus on the key growth drivers and sustainability



## IMPROVEMENT

- Pass on raw material price increases to the market
- Flexibilization of production and processes
- Volume growth & full capacity utilization




## GROWTH

- Increase the availability of Creamino<sup>®</sup> worldwide
- Examine growth opportunities in USA
- Accompany market growth of Creapure<sup>®</sup> through additional CAPEX
- Embed Eminex<sup>®</sup> on the certificate market



## SUSTAINABILITY

- Vision 0 accidents and 0 waste
- Realization of climate roadmap
- Implement EU Taxonomy Regulation and CSRD in an audit-ready manner
- Enjoyment of work – realization of the feedback from the employee survey




# "VERBUND" – FULLY INTEGRATED BUSINESS MODEL

## Benefits of the "Verbund" system approach



- Segment Specialty Chemicals
- Segment Basics & Intermediates



### BENEFITS OF "VERBUND"

- Full control of product quality and specifications
- Lower costs
- Higher financial predictability
- Certainty of supply
- Well positioned to address niche markets
- Economies of scale
- Low carbon footprint

### MEGATRENDS AS GROWTH DRIVERS



POPULATION GROWTH



LONGER LIFE EXPECTANCY



CLIMATE CHANGE



SUSTAINABILITY

# OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries






	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
SPECIALTY CHEMICALS	<b>CREAMINO®</b>	A nutritional additive for poultry and pigs	Feed additive
	<b>Creapure®</b>	Creapure®, premium brand for creatine monohydrate as ingredient in sports & health nutrition	Food supplements
	<b>LIVADUR</b>	Dietary supplement with pure creatine	Food supplements
	<b>Creavitalis®</b>	Creatine for health and food applications	Food supplements
	<b>Dormex®</b>	Plant growth regulator used in fruit production	Agriculture
	<b>BREATHRU'S 301</b>	Additive for plant protection formulations	Agriculture
	<b>Sitofex®</b>	Plant growth regulator used in fruit production	Agriculture
	<b>Silzot HQ</b>	Silicon nitride powder for ceramic applications	Ceramics
	<b>Bioselect®</b>	Highly purified form of guanidine salts	Pharmaceuticals / API
	<b>Cyanamide</b>	An organic compound widely used in agriculture and pharmaceuticals	Agriculture and pharmaceuticals
	<b>DYHARD®</b>	Hardeners and accelerators in powder, paste and liquid form	Hardener & Accelerator Systems for Composite Materials
	<b>Thiourea</b>	Various applications incl. flotation agents and pharmaceutical raw materials	Mining and pharmaceuticals
	<b>Nitroguanidine</b>	Intermediates for explosives and agrochemical products	Agriculture, Automotive, Defense



# OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries



	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
BASICS & INTERMEDIATES	 CaD <sup>®</sup>	Calcium carbide-based mixtures for hot metal desulphurization	Steel industry
	Guanidine Salts	Fuel for airbags, key production of the intermediate product	Automotive
	Dicyandiamide	Versatile intermediate in various markets including the pharmaceutical industry	Pharmaceutical Agriculture
	<b>NITRALZ</b> <sup>®</sup>	Business fields in color, agro and pharmaceutical applications	Pigments Pharmaceutical
	 Eminex <sup>®</sup>	Reduction of methane emissions during storage of manure	Agriculture
	 Perlka <sup>®</sup>	Special calcium cyanamide multi-effect fertilizer	Agriculture
OTHER & HOLDING	<p>Operation of the Trostberg Chemical Park (companies located at the site: Alzchem, BASF, Master Builders Solution, Sika, Firmenich, Aramark, VIACTIV)</p> <p>Site services</p> <p>Other activities not included in the "Specialty Chemicals" or "Basics &amp; Intermediates" segments</p>		

# KEY SHARE DATA

Share Details as of April 26, 2024



SHARES OUTSTANDING 10,176,335

LAST CLOSING PRICE EUR 45.80

MARKET CAPITALIZATION EUR 466 m

TICKER ACT


WKN A2YNT3

ISIN DE000A2YNT30

LISTING Frankfurt Stock Exchange – Prime Standard

DESIGNATED SPONSOR Baader Bank AG  
ODDO BHF Corporate & Markets AG

## SHAREHOLDER STRUCTURE



As of April 2023. The information on the shareholders is based on the figures reported to us by them. Data regarding the free float are provided in accordance with section 2.3 of the "Guide to the DAX Equity Indices".